of the same will not be commensurate with the results likely to be achieved.

(b) Whenever an instance of an SSI unit marketing its product through an Organised Sector Unit comes to the notice of the Government, both the units are directed to seek price approval for concerned formulations wherever necessary. Price fixation of formulation is a continuous process.

(c) and (d) Do not arise in view of reply to (b) above.

Increase in the prices of single ingredient formulations

3735. SHRI CHITTA BASU: Will the Minister of INDUSTRY be pleased to state:

(a) what is the increase in the prices of single ingredient formulations sold under generic name by the ten leading companies engaged in the production of drugs;

(b) what were their prices under DPCO, 1979 and what are their prices now;

(c) what are the various packs of Rifampicin, Pyrazinamide and their combinations for which prices have been fixed under DPCO, 1987 and what is the price fixed for each pack; and

(d) whether any instance of over-charging of price has come to Government's notice?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO): (a) and (b) The required details in the question are quite voluminous. The time and effort required for collection of these will not be commensurate with the results likely to be achieved.

(c) The required details to the extent available are given in the enclosed Statement. (*See* Appendix CXLVII, Annexure No. 131].

(d) Whenever such instance come to the notice of the Government, appropriate action is taken as per the provisions of DPCO, 1987.

Production and imports of formulation

3736. SHRI CHITTA BASU: Will the Minister of INDUSTRY be pleased to refer to the answer to Unstarred Question 1553 given in the Rajya Sabha on the 8th August, 1988 and state:

(a) what is the sales turnover according to ORG of Saridon, Neosporin, Sugranil, Zolandin, Actifed, Nebasulf Dilosyn Fluocort and Benadryl;

(b) what are the bulk drugs on which these formulations are based and whether they are price controlled or not;

(c) what was their production and imports during the last three years, year-wise; and

(d) how many companies are licenced and engaged in the production of each of these drugs?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO): (a) Sales turnover is not monitored.

(b) The required details to the extent available are given in the enclosed Statement. (*See* below) All bulk drugs referred to in the question are price-decontrolled except Paracetamol.

(c) and (d) The required details to the extent available are given at annexure-II. (See Appendix CXLVII, Annexure No. 132)

Statement-I

Sl. No.	Name of the Formulation	Name of the bulk drugs on which formulation is based
1.	Neosporin	Polymixin-B Sulphate, Zinc Bacitracin, Neomycin Sulphate
2.	Actifed	Pseudoophdrine, Triprolidine Hcl.
3.	Saridon	1-Phenyl-2, 3-dimethyl-4-Isopropyl-5-Pyrazolon, Paracetamol 3, -3 diethyl-2, 4-dioxo-Tetrahydropyridine, 1, 3, 7, Trimethyl-2 6-dioxopurine
4.	Suganril	Oxyphenylbutazone
6.	Nebasulf	Neomycin Sulphate, Bacitracin
7.	Dilosyn	Methdilazine
8.	Flucort	Flyocinoone Acetonide
9.	Benadryl	Dephenhydramine Hcl.

Production of Rifampicin in the Organised sector units

3737. SHRI CHITTA BASU: Will the Minister of INDUSTRY be pleased to refer to the Unstarred Question 1554 given in the Rajya Sabha on the 8th August, 1988 and state:

(a) when did the organised sector units register under the delicensing scheme for the production of Rifampicin, what is the capacity registered, what was the phased manufacturing programme of each registered and from what stage of chemical name each unit is registered;

(b) what has been the annual production of each unit from the date of commencement of production and what is the import made during each year and the CIF price of such imports;

(c) whether it is a fact that Kraunkar Labs have been allowed import recently for export of formulations and if so, what is the quantity imported and at what price imports have been made; and

(d) whether any instance of overcharging of price of formulations based on this drug has come to the notice of his Ministry and if so, since when the overinvoicing is going on?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO): (a) Since 1985, several units have registered under the delicensing scheme for the manufacture of Rifampicin. Total capacity registered as on 31-7-88 is 1434 MT. Under the PMP, Rifampicin can be produced from intermediate stage for a period of two years. Thereafter manufacture should be from basic stage.

(b) Production of Rifampicin is not monitored by this Ministry. Details of imports are published in the Monthly Statistics for Foreign Trade in India, Vol. II, Copies of which are available in Parliament Library.

(c) M/s. Krankar Labs. have been allowed to import 625 kgs. of Rifampicin powder for export of formulations. The details of this export have been sought from the company and they have informed that they shall intimate the same as soon as the whole supply is executed.